A good one IMHO from the swamp:

DaubersUP Tuesday, 11/06/18 09:37:35 AM
Re: DaubersUP post# 245120 0
Post #
247713
of 247735
$4.40 a share - Dec 31st 2014: Comparing to 2012 which should show just how undervalued we are with zero FAILURES in the clinic, here are some facts from when we were at the HIGH of IPIX:

Dec 31st 2014 - Share price - $4.40
Cash on hand - 9.4 million
Total OS - 117 Million (ish)
PROGRESS
1) Kevetrin - In Progress Phase 1 - Enrolling in the 10th cohort
2) Prurisol - Successful Phase 1 Completed - Comparing bio-availability b/w P and Ziagen
3) B-Absssi - Successful Phase 2b Completed - Topline data Oct 23rd - full data in 2015 to be announced
4) B-OM - IND filed in Sept 2014 and granted by FDA in Oct 2014

**2 Successful Human Trials to date**

https://www.bamsec.com/filing/147793215001033?cik=1355250
Posted in Feb2015 for Q ending Dec 31st 2014

August 27th 2018 - .40
Cash on hand - 2.4 million
Total OS - 163 Million
PROGRESS
1) Kevetrin - Phase 1 Successful (Solid Tumors)
2) Kevetrin - Phase 2 Successful (Ovarian)
3) Prurisol - Phase 2a Successful (Mild - Moderate Psoriasis)
4) Prurisol - Phase 2b Completed (Moderate - Severe Psoriasis) AWAITING DATE
5) B-OM - Phase 2 Successful (Oral Mucositis - PREVENTION) Leader in an untapped market
6) B-UP/UC - Phase 2 PoC Successful

**5 Additional late stage Human trials SUCCESSFUL - Awaiting data on a Phase 2b for Prurisol**


So to summarize - in 3.5 years IPIX was able to complete 5 SUCCESSFUL human trials and awaiting on data for a phase 2b.
The share count increased by about 45 Million shares.

Go IPIX!!!